https://www.selleckchem.com/pr....oducts/gsk2643943a.h
Highly sensitized (HS) anti-human leukocyte antigens (HLA) patients awaiting kidney transplantation benefit from specific allocation programs. Serological monitoring at 3-month intervals is recommended to prevent unexpected positive crossmatch (XM), but this strategy is not evidence-based. Therefore, we assessed its relevance when using single-antigen flow bead (SAF and screening flow bead (SF assays. We included 166 HS patients awaiting a transplant and assessed their SAFB profile during the year preceding their inclusion. Anti
Me gusta
Comentario
Compartir
